A newly listed Chinese vaccine maker has set its sights on global expansion even as it looks to regain trust in its home market after a scandal last year raised questions about the industry’s quality standards…and guess what. They are currently doing trials on a coronavirus vaccine.
CanSino Biologics jumped 59 per cent in debut trading in Hong Kong on Thursday, reflecting the best first day trading gain in the city since 2017.
Comments are closed.